Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
Status:
Terminated
Trial end date:
2014-03-03
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are the following:
1. To test if the proportion of participants achieving a hemoglobin value greater than or
equal to 10.0 g/dL at any time point after the first dose during the study is greater
than 0.8 when administered de novo darbepoetin alfa once a week (QW) for treatment of
anemia in pediatric patients with chronic kidney disease receiving and not receiving
dialysis, and
2. To test if the proportion of participants achieving a hemoglobin value greater than or
equal to 10.0 g/dL at any time point after the first dose during the study is greater
than 0.8 when administered de novo darbepoetin alfa every 2 weeks (Q2W) for treatment of
anemia in pediatric patients with chronic kidney disease receiving and not receiving
dialysis.